BMS–Orbital Deal Signals a Sharper Bet on In Vivo RNA

Bristol Myers Squibb’s Orbital buy shows how big pharma is methodically building RNA muscle beyond vaccines

19 Jan 2026

In October 2025 Bristol Myers Squibb agreed to buy Orbital Therapeutics, a small firm working on RNA drugs designed to act inside the body. The deal did not promise a scientific revolution. It promised something more prosaic: a way to make RNA work reliably at scale.

RNA shot to fame during the pandemic, when vaccines from Moderna and BioNTech proved the technology’s speed and power. Yet the science itself was old. For years researchers had explored RNA’s use in cancer, immune disorders and inherited disease. What has shifted is the industry’s approach. Instead of betting entire pipelines on untested platforms, big drugmakers are now picking off specific tools they believe are ready to be industrialised.

Orbital focused on in vivo RNA therapies, which avoid removing and re-engineering patients’ cells. That approach has long been blocked by practical problems, notably how to deliver RNA precisely, keep it active long enough and limit side-effects. Orbital’s early data suggested progress on all three. What it lacked was the machinery to push candidates through late-stage trials, regulatory review and global production.

Bristol Myers Squibb supplies that machinery. The firm has spent years trying to rebuild its research engine after patent expiries and failed bets. Folding Orbital into a large organisation is less about daring science than about execution. As one industry watcher put it, the question is no longer whether RNA can work, but whether it can be made dependable.

The transaction reflects a broader rhythm. Moderna and BioNTech have expanded beyond covid into oncology, rare disease and personalised treatments. Venture capital and partnership money continues to flow, but with more modest valuations and clearer milestones. RNA is starting to look less like a miracle and more like a platform, one among several.

Plenty can still go wrong. Small, specialised research teams do not always thrive inside sprawling pharmaceutical firms. Regulators, meanwhile, are still adjusting to fast-evolving genetic tools. Yet progress now comes through accumulation rather than hype.

The deal between Bristol Myers Squibb and Orbital captures that change in mood. RNA’s future will not be built by a single breakthrough. It will be assembled deal by deal, increasingly inside big pharma’s walls.